238 related articles for article (PubMed ID: 30467123)
1. The role of the interleukin (IL)-6/IL-6 receptor axis in cancer.
Taher MY; Davies DM; Maher J
Biochem Soc Trans; 2018 Dec; 46(6):1449-1462. PubMed ID: 30467123
[TBL] [Abstract][Full Text] [Related]
2. Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor α to gp130 expression: fusing experimental insights and dynamic modelling.
Reeh H; Rudolph N; Billing U; Christen H; Streif S; Bullinger E; Schliemann-Bullinger M; Findeisen R; Schaper F; Huber HJ; Dittrich A
Cell Commun Signal; 2019 May; 17(1):46. PubMed ID: 31101051
[TBL] [Abstract][Full Text] [Related]
3. The classic signalling and trans-signalling of interleukin-6 are both injurious in podocyte under high glucose exposure.
Lei CT; Su H; Ye C; Tang H; Gao P; Wan C; He FF; Wang YM; Zhang C
J Cell Mol Med; 2018 Jan; 22(1):251-260. PubMed ID: 28881473
[TBL] [Abstract][Full Text] [Related]
4. Minimal interleukin 6 (IL-6) receptor stalk composition for IL-6 receptor shedding and IL-6 classic signaling.
Baran P; Nitz R; Grötzinger J; Scheller J; Garbers C
J Biol Chem; 2013 May; 288(21):14756-68. PubMed ID: 23564454
[TBL] [Abstract][Full Text] [Related]
5. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
Baran P; Hansen S; Waetzig GH; Akbarzadeh M; Lamertz L; Huber HJ; Ahmadian MR; Moll JM; Scheller J
J Biol Chem; 2018 May; 293(18):6762-6775. PubMed ID: 29559558
[TBL] [Abstract][Full Text] [Related]
6. Increased IL-6 and Potential IL-6 trans-signalling in the airways after an allergen challenge.
Esnault S; Khosravi M; Kelly EA; Liu LY; Bochkov YA; Tattersall MC; Jarjour NN
Clin Exp Allergy; 2021 Apr; 51(4):564-573. PubMed ID: 33471392
[TBL] [Abstract][Full Text] [Related]
7. Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells.
Nishimura R; Moriyama K; Yasukawa K; Mundy GR; Yoneda T
J Bone Miner Res; 1998 May; 13(5):777-85. PubMed ID: 9610741
[TBL] [Abstract][Full Text] [Related]
8. IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
Mihara M; Hashizume M; Yoshida H; Suzuki M; Shiina M
Clin Sci (Lond); 2012 Feb; 122(4):143-59. PubMed ID: 22029668
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 controls recycling and degradation, but not internalization of its receptors.
Flynn CM; Kespohl B; Daunke T; Garbers Y; Düsterhöft S; Rose-John S; Haybaeck J; Lokau J; Aparicio-Siegmund S; Garbers C
J Biol Chem; 2021; 296():100434. PubMed ID: 33610555
[TBL] [Abstract][Full Text] [Related]
10. Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling.
Wolf J; Waetzig GH; Chalaris A; Reinheimer TM; Wege H; Rose-John S; Garbers C
J Biol Chem; 2016 Jul; 291(31):16186-96. PubMed ID: 27226573
[TBL] [Abstract][Full Text] [Related]
11. Dissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer.
Garbers C; Rose-John S
Methods Mol Biol; 2018; 1725():127-140. PubMed ID: 29322414
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 and its receptors: a highly regulated and dynamic system.
Wolf J; Rose-John S; Garbers C
Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
[TBL] [Abstract][Full Text] [Related]
13. Dissecting Interleukin-6 Classic and Trans-signaling in Inflammation and Cancer.
Garbers C; Rose-John S
Methods Mol Biol; 2023; 2691():207-224. PubMed ID: 37355548
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor.
Garbers C; Thaiss W; Jones GW; Waetzig GH; Lorenzen I; Guilhot F; Lissilaa R; Ferlin WG; Grötzinger J; Jones SA; Rose-John S; Scheller J
J Biol Chem; 2011 Dec; 286(50):42959-70. PubMed ID: 21990364
[TBL] [Abstract][Full Text] [Related]
15. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130.
Tenhumberg S; Waetzig GH; Chalaris A; Rabe B; Seegert D; Scheller J; Rose-John S; Grötzinger J
J Biol Chem; 2008 Oct; 283(40):27200-7. PubMed ID: 18650419
[TBL] [Abstract][Full Text] [Related]
16. Activation of the signal transducer gp130 by interleukin-11 and interleukin-6 is mediated by similar molecular interactions.
Dahmen H; Horsten U; Küster A; Jacques Y; Minvielle S; Kerr IM; Ciliberto G; Paonessa G; Heinrich PC; Müller-Newen G
Biochem J; 1998 May; 331 ( Pt 3)(Pt 3):695-702. PubMed ID: 9560294
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6: A Masterplayer in the Cytokine Network.
Uciechowski P; Dempke WCM
Oncology; 2020; 98(3):131-137. PubMed ID: 31958792
[TBL] [Abstract][Full Text] [Related]
18. Function and proteolytic generation of the soluble interleukin-6 receptor in health and disease.
Schumertl T; Lokau J; Rose-John S; Garbers C
Biochim Biophys Acta Mol Cell Res; 2022 Jan; 1869(1):119143. PubMed ID: 34626681
[TBL] [Abstract][Full Text] [Related]
19. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.
Rose-John S
Int J Biol Sci; 2012; 8(9):1237-47. PubMed ID: 23136552
[TBL] [Abstract][Full Text] [Related]
20. The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation.
Rose-John S
Clin Pharmacol Ther; 2017 Oct; 102(4):591-598. PubMed ID: 28675418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
